Well, that's one take on it, the other is the ASX doesn't know shit from clay. Telix is considerably undervalued and so is Neuren. Neuren's 2591 asset isn't even priced in and it's the crown jewel of the company potentially worth billions.
CUV's revenues still rising which is good to see, only a nihilist would see it as anything other than positive. But questions linger over execution and conflicts of interest concerning the CEO. If vitiligo is approved, that will go some way to assuaging concerns that this company IS able to conduct large Phase 3 trials and bodes well for the other indications (Parkinson's et al). I would consider that a major inflection point and the opportunity to leave the misery of the last decade behind.
CUV Price at posting:
$15.41 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)